Raptor Pharmaceutical (RPTP) 8.12 $RPTP
The Federal Reserve Playing Analyst Damaging to Biotechnology Companies
ACCESSWIRE - Wed Jul 30, 9:06AM CDT
WHITEFISH, MT / July 30, 2014 / The July 15 U.S. Federal Reserve report on monetary policy touched off a barrage of barely polite and not very muted commentary from one end of the web to the other this past week with 32 simple words: "Equity valuations of smaller firms as well as social media and biotechnology firms appear to be stretched, with ratios of prices to forward earnings remaining high relative to historical norms." The release of the report to Congress coincided with the start of Federal Reserve Chairwoman Janet Yellen's testimony before a Congressional committee. NBI, the Nasdaq Biotechnology Index, slumped from around 2,700 on Tuesday to a low of 2,536 on Thursday, a 6% nosedive, before paring the losses with an up day on Friday. Of the 120 companies in the NBI, 101 closed in the red last week, including Ligand Pharma (NASDAQ: LGND) shedding 19.4% and Raptor Pharma (NASDAQ: RPTP) falling 18.7%.
Raptor Pharmaceutical to Hold Second Quarter 2014 Financial Results Webcast and Conference Call
GlobeNewswire - Mon Jul 28, 3:15PM CDT
Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today announced that it will release second quarter 2014 financial results after market close on Thursday, August 7, 2014. Raptor management will host a webcast and conference call at 4:30 p.m. EDT (1:30 p.m. PDT) that day to discuss the financial results and provide a corporate update.
Galectin, Intercept, Others Vying for Lead Drugs in NASH Epidemic
ACCESSWIRE - Thu Jul 24, 9:03AM CDT
WHITEFISH, MT / July 24, 2014 / Fat is driving the bus these days in one narrow, but widening, biotech sector as companies strive for dominance. Among these are Galectin Therapeutics Inc. (NASDAQ: GALT), Intercept Pharmaceuticals (NASDAQ: ICPT), Raptor Pharmaceuticals (NASDAQ: RPTP) and Gilead Sciences (NASDAQ: GILD), all of which are in search of a cure for one stage or another of "fatty liver disease."
Executive Appointments and Technical Updates - Analyst Notes on Aeri Pharmaceuticals, DaVita, Prana Biotechnology, Raptor and Avanir Pharmaceuticals
PR Newswire - Mon Jul 14, 4:10AM CDT
Today, Analysts Review released its analysts' notes regarding Aeri Pharmaceuticals, Inc. (NASDAQ: AERI), DaVita HealthCare Partners Inc. (NYSE: DVA), Prana Biotechnology Ltd. (NASDAQ: PRAN), Raptor Pharmaceuticals Corp. (NASDAQ: RPTP) and Avanir Pharmaceuticals (NASDAQ: AVNR). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/4726-100free.
3 Stocks Spiking on Unusual Volume
at The Street - Thu Jul 10, 8:14AM CDT
Often when above-average volume moves into an equity, it precedes a large spike in volatility.
Raptor Pharmaceuticals CEO to Retire, Appoints Successor - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jul 08, 4:10PM CDT
Raptor Pharma (RPTP) announced a change at the helm.
Raptor Announces CEO Succession Plan; Dr. Christopher Starr to Retire as CEO at Year-end 2014, Julie Anne Smith Named President and CEO-Designate
GlobeNewswire - Mon Jul 07, 3:04PM CDT
Raptor Pharmaceuticals (Nasdaq:RPTP) today announced that Julie Anne Smith, Executive Vice President, Strategy and Chief Operating Officer at Raptor, has been named President and CEO-designate effective immediately. Smith will succeed Christopher Starr, Ph.D., as Chief Executive Officer and will join the Board effective January 1, 2015. As President and CEO-designate, Smith will oversee all company operations based out of Raptor's headquarters in Novato, California. Dr. Starr will continue working closely with Smith during this transition period, will remain on the Board of Directors and will consult on Raptor development projects following the succession.
Raptor Pharmaceutical Enters Into $70 Million Financing Transaction and Amended Loan Agreement With HealthCare Royalty Partners
GlobeNewswire - Tue Jul 01, 4:13PM CDT
Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today announced that it has entered into agreements for $70 million in funding from HealthCare Royalty Partners (HC Royalty) and its affiliates in a private placement. The funding includes $60 million in new convertible senior notes and an additional $10 million of funding pursuant to an amended and restated loan agreement, originally signed on December 20, 2012. The new capital will be used for expansion of the company's manufacturing capacity, expansion of commercial operations in Europe, advancement of the company's development programs and general corporate purposes, including working capital. Closing is expected to occur by the end of July 2014 and is subject to customary closing conditions under both the convertible note financing agreement and the amended and restated loan agreement.
Are Investors Wrong About Raptor Pharmaceuticals?
George Budwell, The Motley Fool - Motley Fool - Thu Jun 26, 4:00PM CDT
A rapidly increasing short interest in a stock is sometimes a good signal that an investment may not be a good idea. Even so, it's critical to understand why shorts are moving into the stock before making any investment decisions. Raptor...
Data Published in Journal of Pediatrics Demonstrated That PROCYSBI(R) Improved Quality of Life and Preserved Kidney Function in Cystinosis Patients
GlobeNewswire - Tue Jun 24, 6:00AM CDT
Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today announced that data from its open label extension study of delayed-release cysteamine bitartrate (PROCYSBI) has been published in the Journal of Pediatrics [DOI: 10.1016/j.jpeds.2014.05.013]. The study demonstrated that patients with nephropathic cystinosis who took PROCYSBI for two years were able to sustain optimal cystine control in their white blood cells and preserve kidney function over the long term, and had significant improvements in social, school and total functioning based on validated quality of life measurement scales.
FDA Approvals, Agreements, Investor Conference Schedules, and Technical Updates - Analyst Notes on Covidien, Pacira, Techne, OraSure and Raptor Pharmaceutical
PR Newswire - Tue Jun 17, 4:20AM CDT
Today, Analysts Review released its analysts' notes regarding Covidien plc (NYSE: COV), Pacira Pharmaceuticals Inc. (NASDAQ: PCRX), Techne Corp. (NASDAQ: TECH), OraSure Technologies Inc. (NASDAQ: OSUR) and Raptor Pharmaceutical Corp. (NASDAQ: RPTP). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/3789-100free.
Raptor Pharma (RPTP) is in Overbought Territory: What's Next? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Jun 16, 9:56AM CDT
Raptor Pharma (RPTP) is in Overbought Territory: What’s Next?
Raptor Pharmaceutical to Participate in Three Upcoming Investor Conferences in June
GlobeNewswire - Tue Jun 10, 7:00AM CDT
Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today announced that company management will participate in three upcoming investor conferences in June.
Spasticity - Pipeline Review, H1 2014
M2 - Thu May 29, 6:54AM CDT
Research and Markets (http://www.researchandmarkets.com/research/nwnpbd/spasticity) has announced the addition of the "Spasticity - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Spasticity, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Spasticity and special features on late-stage and discontinued projects. This report features investigatory drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updates following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Scope - The report provides a snapshot of the global therapeutic landscape of Spasticity - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Spasticity and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Spasticity products under development by companies and universities/research institutes based on information derived from company and industry-specific sources Companies Mentioned: - Addex Therapeutics - BiRDS Pharma GmbH - Canbex Therapeutics Ltd. - Concert Pharmaceuticals, Inc. - Echo Pharmaceuticals B.V. - Escape Therapeutics, Inc. - GW Pharmaceuticals plc - Intec Pharma ltd. - Merz Pharma GmbH & Co. KgaA - Novartis AG - Osmotica Pharmaceutical Corp. - Raptor Pharmaceuticals Corp. - Sanochemia Pharmazeutika AG - SciFluor Life Sciences, LLC For more information visit http://www.researchandmarkets.com/research/nwnpbd/spasticity
3 Stocks Under $10 Moving Higher
at The Street - Wed May 28, 6:45AM CDT
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
These Stocks Are Getting Hit Hardest During March's Biotech 'Correction'
at The Street - Tue Mar 25, 1:35PM CDT
Geron, Celldex Therapeutics, Xoma and Cytrx are among the drug stocks losing more than 30% of their value in the past month.
Health Care Equities Analysis -- Research on Raptor Pharma, Intercept Pharma, KYTHERA Biopharma, and Synergy Pharma
PR Newswire - Tue Mar 25, 10:00AM CDT
On Monday, March 24, 2014, the NASDAQ Composite finished at 4,226.39, down 1.18%, the Dow Jones Industrial Average fell 0.16% to 16,276.69, and the S&P 500 closed at 1,857.44, down 0.49%. The losses were broad based with eight out of ten sectors ending the session in negative. The S&P 500 Health Care Sector Index finished the day at 666.18, down 1.41%, and the same has declined 2.67% in the last one month. Investor-Edge has initiated coverage on the following equities: Raptor Pharmaceutical Corp. (NASDAQ: RPTP), Intercept Pharmaceuticals Inc. (NASDAQ: ICPT), KYTHERA Biopharmaceuticals Inc. (NASDAQ: KYTH) and Synergy Pharmaceuticals Inc. (NASDAQ: SGYP). Free technical research on RPTP, ICPT, KYTH and SGYP can be downloaded upon signing up at:
Courtagen Life Sciences Announces Collaboration with Raptor Pharmaceuticals for Leigh Syndrome and Other Mitochondrial Disorders
Business Wire - Tue Mar 25, 6:30AM CDT
Courtagen Life Sciences announced today an agreement with Raptor Pharmaceuticals Inc. to provide genetic testing in the clinical trial for RP103 as a potential treatment for Leigh syndrome and other mitochondrial disorders. Leigh syndrome is a severe neurological disorder caused by genetic defects in mitochondrial or nuclear DNA affecting respiratory chain function that typically results in death within the first decade of life.
Approvals, Financial Results, and Stock Movements - Analyst Notes on Merck, Novartis, Raptor, Akorn, and Pacira
PR Newswire - Wed Mar 19, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Merck & Co., Inc. (NYSE: MRK), Novartis AG (NYSE: NVS), Raptor Pharmaceutical Corp. (NASDAQ: RPTP), Akorn, Inc. (NASDAQ: AKRX), and Pacira Pharmaceuticals Inc. (NASDAQ: PCRX). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Why Plug Power, Aeropostale, and Raptor Pharmaceuticals Tumbled Today
Dan Caplinger, The Motley Fool - Motley Fool - Fri Mar 14, 7:30PM CDT
Friday's market action involved many of the same concerns that have plagued stock investors all week, including the planned referendum in Crimea on whether to break off from Ukraine and join Russia. Nervousness led to small declines for broad market...
The Federal Reserve Playing Analyst Damaging to Biotechnology Companies
ACCESSWIRE - Wed Jul 30, 9:06AM CDT
WHITEFISH, MT / July 30, 2014 / The July 15 U.S. Federal Reserve report on monetary policy touched off a barrage of barely polite and not very muted commentary from one end of the web to the other this past week with 32 simple words: "Equity valuations of smaller firms as well as social media and biotechnology firms appear to be stretched, with ratios of prices to forward earnings remaining high relative to historical norms." The release of the report to Congress coincided with the start of Federal Reserve Chairwoman Janet Yellen's testimony before a Congressional committee. NBI, the Nasdaq Biotechnology Index, slumped from around 2,700 on Tuesday to a low of 2,536 on Thursday, a 6% nosedive, before paring the losses with an up day on Friday. Of the 120 companies in the NBI, 101 closed in the red last week, including Ligand Pharma (NASDAQ: LGND) shedding 19.4% and Raptor Pharma (NASDAQ: RPTP) falling 18.7%.
Raptor Pharmaceutical to Hold Second Quarter 2014 Financial Results Webcast and Conference Call
GlobeNewswire - Mon Jul 28, 3:15PM CDT
Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today announced that it will release second quarter 2014 financial results after market close on Thursday, August 7, 2014. Raptor management will host a webcast and conference call at 4:30 p.m. EDT (1:30 p.m. PDT) that day to discuss the financial results and provide a corporate update.
Galectin, Intercept, Others Vying for Lead Drugs in NASH Epidemic
ACCESSWIRE - Thu Jul 24, 9:03AM CDT
WHITEFISH, MT / July 24, 2014 / Fat is driving the bus these days in one narrow, but widening, biotech sector as companies strive for dominance. Among these are Galectin Therapeutics Inc. (NASDAQ: GALT), Intercept Pharmaceuticals (NASDAQ: ICPT), Raptor Pharmaceuticals (NASDAQ: RPTP) and Gilead Sciences (NASDAQ: GILD), all of which are in search of a cure for one stage or another of "fatty liver disease."
Executive Appointments and Technical Updates - Analyst Notes on Aeri Pharmaceuticals, DaVita, Prana Biotechnology, Raptor and Avanir Pharmaceuticals
PR Newswire - Mon Jul 14, 4:10AM CDT
Today, Analysts Review released its analysts' notes regarding Aeri Pharmaceuticals, Inc. (NASDAQ: AERI), DaVita HealthCare Partners Inc. (NYSE: DVA), Prana Biotechnology Ltd. (NASDAQ: PRAN), Raptor Pharmaceuticals Corp. (NASDAQ: RPTP) and Avanir Pharmaceuticals (NASDAQ: AVNR). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/4726-100free.
3 Stocks Spiking on Unusual Volume
at The Street - Thu Jul 10, 8:14AM CDT
Often when above-average volume moves into an equity, it precedes a large spike in volatility.
Raptor Pharmaceuticals CEO to Retire, Appoints Successor - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jul 08, 4:10PM CDT
Raptor Pharma (RPTP) announced a change at the helm.
Raptor Announces CEO Succession Plan; Dr. Christopher Starr to Retire as CEO at Year-end 2014, Julie Anne Smith Named President and CEO-Designate
GlobeNewswire - Mon Jul 07, 3:04PM CDT
Raptor Pharmaceuticals (Nasdaq:RPTP) today announced that Julie Anne Smith, Executive Vice President, Strategy and Chief Operating Officer at Raptor, has been named President and CEO-designate effective immediately. Smith will succeed Christopher Starr, Ph.D., as Chief Executive Officer and will join the Board effective January 1, 2015. As President and CEO-designate, Smith will oversee all company operations based out of Raptor's headquarters in Novato, California. Dr. Starr will continue working closely with Smith during this transition period, will remain on the Board of Directors and will consult on Raptor development projects following the succession.
Raptor Pharmaceutical Enters Into $70 Million Financing Transaction and Amended Loan Agreement With HealthCare Royalty Partners
GlobeNewswire - Tue Jul 01, 4:13PM CDT
Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today announced that it has entered into agreements for $70 million in funding from HealthCare Royalty Partners (HC Royalty) and its affiliates in a private placement. The funding includes $60 million in new convertible senior notes and an additional $10 million of funding pursuant to an amended and restated loan agreement, originally signed on December 20, 2012. The new capital will be used for expansion of the company's manufacturing capacity, expansion of commercial operations in Europe, advancement of the company's development programs and general corporate purposes, including working capital. Closing is expected to occur by the end of July 2014 and is subject to customary closing conditions under both the convertible note financing agreement and the amended and restated loan agreement.
Are Investors Wrong About Raptor Pharmaceuticals?
George Budwell, The Motley Fool - Motley Fool - Thu Jun 26, 4:00PM CDT
A rapidly increasing short interest in a stock is sometimes a good signal that an investment may not be a good idea. Even so, it's critical to understand why shorts are moving into the stock before making any investment decisions. Raptor...
Data Published in Journal of Pediatrics Demonstrated That PROCYSBI(R) Improved Quality of Life and Preserved Kidney Function in Cystinosis Patients
GlobeNewswire - Tue Jun 24, 6:00AM CDT
Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today announced that data from its open label extension study of delayed-release cysteamine bitartrate (PROCYSBI) has been published in the Journal of Pediatrics [DOI: 10.1016/j.jpeds.2014.05.013]. The study demonstrated that patients with nephropathic cystinosis who took PROCYSBI for two years were able to sustain optimal cystine control in their white blood cells and preserve kidney function over the long term, and had significant improvements in social, school and total functioning based on validated quality of life measurement scales.
FDA Approvals, Agreements, Investor Conference Schedules, and Technical Updates - Analyst Notes on Covidien, Pacira, Techne, OraSure and Raptor Pharmaceutical
PR Newswire - Tue Jun 17, 4:20AM CDT
Today, Analysts Review released its analysts' notes regarding Covidien plc (NYSE: COV), Pacira Pharmaceuticals Inc. (NASDAQ: PCRX), Techne Corp. (NASDAQ: TECH), OraSure Technologies Inc. (NASDAQ: OSUR) and Raptor Pharmaceutical Corp. (NASDAQ: RPTP). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/3789-100free.
Raptor Pharma (RPTP) is in Overbought Territory: What's Next? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Jun 16, 9:56AM CDT
Raptor Pharma (RPTP) is in Overbought Territory: What’s Next?
Raptor Pharmaceutical to Participate in Three Upcoming Investor Conferences in June
GlobeNewswire - Tue Jun 10, 7:00AM CDT
Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today announced that company management will participate in three upcoming investor conferences in June.
Spasticity - Pipeline Review, H1 2014
M2 - Thu May 29, 6:54AM CDT
Research and Markets (http://www.researchandmarkets.com/research/nwnpbd/spasticity) has announced the addition of the "Spasticity - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Spasticity, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Spasticity and special features on late-stage and discontinued projects. This report features investigatory drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updates following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Scope - The report provides a snapshot of the global therapeutic landscape of Spasticity - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Spasticity and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Spasticity products under development by companies and universities/research institutes based on information derived from company and industry-specific sources Companies Mentioned: - Addex Therapeutics - BiRDS Pharma GmbH - Canbex Therapeutics Ltd. - Concert Pharmaceuticals, Inc. - Echo Pharmaceuticals B.V. - Escape Therapeutics, Inc. - GW Pharmaceuticals plc - Intec Pharma ltd. - Merz Pharma GmbH & Co. KgaA - Novartis AG - Osmotica Pharmaceutical Corp. - Raptor Pharmaceuticals Corp. - Sanochemia Pharmazeutika AG - SciFluor Life Sciences, LLC For more information visit http://www.researchandmarkets.com/research/nwnpbd/spasticity
3 Stocks Under $10 Moving Higher
at The Street - Wed May 28, 6:45AM CDT
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
These Stocks Are Getting Hit Hardest During March's Biotech 'Correction'
at The Street - Tue Mar 25, 1:35PM CDT
Geron, Celldex Therapeutics, Xoma and Cytrx are among the drug stocks losing more than 30% of their value in the past month.
Health Care Equities Analysis -- Research on Raptor Pharma, Intercept Pharma, KYTHERA Biopharma, and Synergy Pharma
PR Newswire - Tue Mar 25, 10:00AM CDT
On Monday, March 24, 2014, the NASDAQ Composite finished at 4,226.39, down 1.18%, the Dow Jones Industrial Average fell 0.16% to 16,276.69, and the S&P 500 closed at 1,857.44, down 0.49%. The losses were broad based with eight out of ten sectors ending the session in negative. The S&P 500 Health Care Sector Index finished the day at 666.18, down 1.41%, and the same has declined 2.67% in the last one month. Investor-Edge has initiated coverage on the following equities: Raptor Pharmaceutical Corp. (NASDAQ: RPTP), Intercept Pharmaceuticals Inc. (NASDAQ: ICPT), KYTHERA Biopharmaceuticals Inc. (NASDAQ: KYTH) and Synergy Pharmaceuticals Inc. (NASDAQ: SGYP). Free technical research on RPTP, ICPT, KYTH and SGYP can be downloaded upon signing up at:
Courtagen Life Sciences Announces Collaboration with Raptor Pharmaceuticals for Leigh Syndrome and Other Mitochondrial Disorders
Business Wire - Tue Mar 25, 6:30AM CDT
Courtagen Life Sciences announced today an agreement with Raptor Pharmaceuticals Inc. to provide genetic testing in the clinical trial for RP103 as a potential treatment for Leigh syndrome and other mitochondrial disorders. Leigh syndrome is a severe neurological disorder caused by genetic defects in mitochondrial or nuclear DNA affecting respiratory chain function that typically results in death within the first decade of life.
Approvals, Financial Results, and Stock Movements - Analyst Notes on Merck, Novartis, Raptor, Akorn, and Pacira
PR Newswire - Wed Mar 19, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Merck & Co., Inc. (NYSE: MRK), Novartis AG (NYSE: NVS), Raptor Pharmaceutical Corp. (NASDAQ: RPTP), Akorn, Inc. (NASDAQ: AKRX), and Pacira Pharmaceuticals Inc. (NASDAQ: PCRX). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Why Plug Power, Aeropostale, and Raptor Pharmaceuticals Tumbled Today
Dan Caplinger, The Motley Fool - Motley Fool - Fri Mar 14, 7:30PM CDT
Friday's market action involved many of the same concerns that have plagued stock investors all week, including the planned referendum in Crimea on whether to break off from Ukraine and join Russia. Nervousness led to small declines for broad market...
